title: Remaining controversies in the upfront management of advanced ovarian cancer.
abstract: Ovarian cancer (OC) is one of the leading causes of cancer-related death in women. In the last decades, a lot of energy and resources have been put into a number of clinical trials, with some success. Nevertheless, the prognosis of patients diagnosed with advanced disease remains extremely poor. As research moved forward, some crucial questions with regard to the optimal upfront management of patients with advanced OC (AOC) have remained unanswered. In this article, we review the rationale behind these controversial issues, and provide the levels of evidence supporting the current recommendations for AOC management.
authors.affiliation: Unité de Chimiothérapie, Institut Jules Bordet, Brussels, Belgium. max.mano@northglasgow.scot.nhs.uk
authors.forename: M S
authors.initials: MS
authors.lastname: Mano
authors.forename: A
authors.initials: A
authors.lastname: Awada
authors.forename: A
authors.initials: A
authors.lastname: Minisini
authors.forename: G
authors.initials: G
authors.lastname: Atalay
authors.forename: L D
authors.initials: LD
authors.lastname: Lago
authors.forename: F
authors.initials: F
authors.lastname: Cardoso
authors.forename: M
authors.initials: M
authors.lastname: Piccart
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D011379:Prognosis